Processa Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Processa Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $5.0K | Sep 25, 2017 |
| FY2016 | Dec 31, 2015 | $113.4K | Sep 25, 2017 |
| FY2015 | Dec 31, 2014 | $107.2K | Jun 19, 2017 |
| FY2014 | Dec 31, 2013 | $312.5K | Apr 14, 2015 |
| FY2013 | Dec 31, 2012 | $192.1K | Mar 27, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2021 | $0 | Mar 30, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $5.0K | Sep 25, 2017 |
| FY2016 | Dec 31, 2015 | $74.6K | Sep 25, 2017 |
| FY2015 | Dec 31, 2014 | $101.1K | Jun 19, 2017 |
| FY2014 | Dec 31, 2013 | $253.5K | Apr 14, 2015 |
| FY2013 | Dec 31, 2012 | $190.1K | Mar 27, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $5.0K | Sep 25, 2017 |
| FY2016 | Dec 31, 2015 | ($12.5K) | Sep 25, 2017 |
| FY2015 | Dec 31, 2014 | $40.4K | Jun 19, 2017 |
| FY2014 | Dec 31, 2013 | $124.5K | Apr 14, 2015 |
| FY2013 | Dec 31, 2012 | $58.9K | Mar 27, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.56M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($11.85M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($11.12M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($27.42M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($11.43M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($14.41M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($3.36M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($3.77M) | Mar 6, 2020 |
| FY2017 | Dec 31, 2017 | ($633.9K) | Apr 16, 2018 |
| FY2017 | Sep 30, 2017 | ($711.6K) | Apr 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.99M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($12.05M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($11.46M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($27.53M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($12.13M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($15.14M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($3.94M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($4.52M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | ($1.80M) | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | ($1.92M) | Apr 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.80M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $11.49M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $6.88M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.17M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $2.32M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.09M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $964.2K | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | $1.54M | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $29.2K | Sep 25, 2017 |
| FY2015 | Dec 31, 2014 | $178.1K | Jun 19, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.44M | Apr 8, 2019 |
| FY2018 | Dec 31, 2017 | $838.3K | Apr 8, 2019 |
| FY2016 | Dec 31, 2016 | $70.0K | Sep 25, 2017 |
| FY2016 | Dec 31, 2015 | $945.5K | Sep 25, 2017 |
| FY2015 | Dec 31, 2014 | $2.02M | Jun 19, 2017 |
| FY2014 | Dec 31, 2013 | $2.82M | Apr 14, 2015 |
| FY2013 | Dec 31, 2012 | $1.88M | Mar 27, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.39M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($11.25M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($8.06M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($9.61M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($8.72M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($3.14M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($2.75M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($3.71M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | ($1.65M) | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | ($2.16M) | Apr 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.2K | Mar 20, 2025 |
| FY2024 | Dec 31, 2023 | $2.8K | Mar 20, 2025 |
| FY2018 | Dec 31, 2017 | $20.6K | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | $23.8K | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.4K | Sep 25, 2017 |
| FY2015 | Dec 31, 2014 | $11.0K | Jun 19, 2017 |
| FY2014 | Dec 31, 2013 | $27.7K | Apr 14, 2015 |
| FY2013 | Dec 31, 2012 | $334.3K | Mar 27, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.81M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.23M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $5.79M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $8.62M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $26.46M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $25.21M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $10.88M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $12.48M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $2.98M | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | $2.36M | Apr 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.24M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.53M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $797.5K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.15M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $978.4K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.27M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $2.87M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.78M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $2.61M | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | $97.7K | Apr 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.58M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.70M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $4.99M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $7.47M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $25.49M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $22.94M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $8.01M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $9.70M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $373.2K | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | ($2.27M) | Apr 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($100.78M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($87.22M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($75.37M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($64.25M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($36.82M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($25.40M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($10.98M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($7.62M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | ($3.86M) | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | ($2.00M) | Apr 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.54M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.19M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $4.71M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $6.50M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $16.50M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $15.42M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $691.5K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.74M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $2.85M | Apr 8, 2019 |
| FY2018 | Dec 31, 2016 | $1.07M | Apr 8, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (10) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (96) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (34) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2017 | Dec 31, 2017 | 0 | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 16, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (10) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (96) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (34) | Mar 29, 2024 |
| FY2017 | Dec 31, 2017 | 0 | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 16, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.57M | Mar 18, 2026 |
| FY2025 | Dec 17, 2025 | 2.28M | Mar 18, 2026 |
| FY2025 | Dec 16, 2025 | 56.99M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 148,108 | Mar 18, 2026 |
| FY2024 | Jan 22, 2024 | 1.29M | Mar 20, 2025 |
| FY2024 | Jan 21, 2024 | 24.61M | Mar 20, 2025 |
| FY2024 | Dec 31, 2023 | 1.29M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 801,774 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 15.71M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 14.18M | Mar 30, 2022 |